Al‐Badri A, Tahhan AS, Sabbak N, et al. - Given that in patients with coronary artery disease, multiple biomarkers have been independently as well as additively related to major adverse cardiovascular events, so, researchers undertook this inquiry among symptomatic patients with no obstructive coronary artery disease in order to determine the prognostic significance of suPAR (soluble urokinase‐type plasminogen activator receptor) and hsTnI (high‐sensitivity troponin I) levels in this patient sample. They formulated a hypothesis that high levels of these biomarkers will be related to the risk of future adverse consequences. Participants were 556 patients in total. Experts computed a biomarker risk score by counting the number of biomarkers above the median in this cohort (suPAR > 2523 pg/mL and hsTnI > 2.7 pg/mL). Findings revealed that higher levels of suPAR as well as hsTnI were independently and additively related to an increased risk of adverse events in this patient population. There is a requirement for further inquiry to determine if changes of these biomarkers will improve risk in these patients.